GlassScriptPhysician profile
Virginia Ferlan
NPI 1225119845
$929.60
in general payments reported to CMS, 2019-2025
15 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.03 · 2020: $65.22 · 2021: $73.36 · 2022: $82.45 · 2023: $217 · 2024: $212 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $177.43 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $138.40 | 2023-2024 | |
| Astellas Pharma US INC | $103.78 | 2023-2024 | Veozah |
| Avion Pharmaceuticals | $91.36 | 2019-2021 | |
| Millicent US INC | $83.68 | 2025 | Femlyv, Femring, Intrarosa |
| Organon LLC | $63.98 | 2022-2025 | Nexplanon |
| Therapeuticsmd, INC. | $59.34 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.06 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $36.86 | 2024-2025 | Myfembree |
| Exact Sciences Corporation | $23.73 | 2025 | The Cologuard Plus Collection Kit |
| Exeltis, USA INC. | $23.27 | 2025 | Slynd |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.35 | 2024 | Xifaxan, Trulance |
| Pfizer INC. | $17.46 | 2022 | |
| Aspira Women'S Health INC | $16.97 | 2024 | Ova1 |
| Mission Pharmacal Company | $14.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Ferlan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.